Theodore R Schroeder
CIK 1378690 · Chief Executive Officer · last filed 2026-05-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CADX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PHAT | Director | 45,122 | $5.90 | $266.2K | $0 | 2 | 2026-05-21 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | — | $221.38 | — | $0 | 13 | 2026-01-07 |
| Nabriva Therapeutics plc (NBRV) Delisted | Chief Executive Officer | 12,459 | $1.42 | $17.7K | $203.3K | 68 | 2023-01-31 |
| OTONOMY, INC. (OTIC) Delisted | Director | — | $0.08 | — | $0 | 8 | 2022-06-23 |
| COLL | Director | 11,007 | $22.91 | $252.2K | $0 | 2 | 2020-05-22 |
| COLLEGIUM PHARMACEUTICAL, INC (ESPR) Delisted | Director | 6,960 | $3.18 | $22.1K | $0 | 4 | 2019-04-29 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | 0 | — | — | $0 | 2 | 2015-05-08 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | President, CEO | 320,164 | — | — | -$1.61M | 17 | 2014-02-12 |
| Trius Therapeutics Inc (TSRX) Delisted | Director | — | — | — | $0 | 4 | 2013-05-23 |
Recent Filings · Page 8 of 13
122 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-25 | OTONOMY, INC. (OTIC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-03 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −1,211 | -$1.4K | EDGAR |
| 2020-05-22 | COLL | Grant (A) | +4,047 | $0 | EDGAR |
| 2020-05-04 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −1,211 | -$664 | EDGAR |
| 2020-04-02 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −1,211 | -$696 | EDGAR |
| 2020-03-03 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −1,211 | -$1.6K | EDGAR |
| 2020-02-10 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | +343,800 | $0 | EDGAR |
| 2020-02-04 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −16,276 | -$22.0K | EDGAR |
| 2019-08-28 | Nabriva Therapeutics plc (NBRV) Delisted | Buy (P) | +50,000 | $89.5K | EDGAR |
| 2019-07-25 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | +6,748 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.